Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Scientific Reports
|
March 17, 2016
The Hippo pathway member YAP enhances human neural crest cell fate and migration
Christopher J Hindley, Alexandra Larisa Condurat, Vishal Menon, et al.
Journal of Cardiac Failure
|
August 4, 2025
Effect of Time Since Heart Failure Diagnosis or Hospitalization on the Cost-Effectiveness of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Ankeet S Bhatt, Rudolf A DE Boer, David Booth, et al.
Plos One
|
July 5, 2013
Combined flow cytometric analysis of surface and intracellular antigens reveals surface molecule markers of human neuropoiesis
Gizem Turaç, Christopher J Hindley, Ria Thomas, et al.
Clinical Orthopaedics and Related Research
|
October 27, 2015
Does Postoperative Radiation Decrease Heterotopic Ossification After the Kocher-Langenbeck Approach for Acetabular Fracture?
Jason A Davis, Brennan Roper, John W Munz, et al.
Neuron
|
August 15, 2008
Mouse cones require an arrestin for normal inactivation of phototransduction
Sergei S Nikonov, Bruce M Brown, Jason A Davis, et al.
European Journal of Heart Failure
|
June 30, 2021
Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF
Phil McEwan, Piotr Ponikowski, Jason A Davis, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
June 8, 2012
An S-opsin knock-in mouse (F81Y) reveals a role for the native ligand 11-cis-retinal in cone opsin biosynthesis
Christine Insinna, Lauren L Daniele, Jason A Davis, et al.
European Journal of Heart Failure
|
March 21, 2024
Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA-HF and DELIVER data
Jason A Davis, David Booth, Phil McEwan, et al.
European Journal of Heart Failure
|
June 22, 2023
The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health-economic analysis of the DELIVER trial
David Booth, Jason A Davis, Phil McEwan, et al.
Clinical Kidney Journal
|
February 23, 2024
Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial
Phil McEwan, Jason A Davis, Peter D Gabb, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Scientific Reports
|
March 17, 2016
The Hippo pathway member YAP enhances human neural crest cell fate and migration
Christopher J Hindley, Alexandra Larisa Condurat, Vishal Menon, et al.
Journal of Cardiac Failure
|
August 4, 2025
Effect of Time Since Heart Failure Diagnosis or Hospitalization on the Cost-Effectiveness of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Ankeet S Bhatt, Rudolf A DE Boer, David Booth, et al.
Plos One
|
July 5, 2013
Combined flow cytometric analysis of surface and intracellular antigens reveals surface molecule markers of human neuropoiesis
Gizem Turaç, Christopher J Hindley, Ria Thomas, et al.
Clinical Orthopaedics and Related Research
|
October 27, 2015
Does Postoperative Radiation Decrease Heterotopic Ossification After the Kocher-Langenbeck Approach for Acetabular Fracture?
Jason A Davis, Brennan Roper, John W Munz, et al.
Neuron
|
August 15, 2008
Mouse cones require an arrestin for normal inactivation of phototransduction
Sergei S Nikonov, Bruce M Brown, Jason A Davis, et al.
European Journal of Heart Failure
|
June 30, 2021
Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF
Phil McEwan, Piotr Ponikowski, Jason A Davis, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
June 8, 2012
An S-opsin knock-in mouse (F81Y) reveals a role for the native ligand 11-cis-retinal in cone opsin biosynthesis
Christine Insinna, Lauren L Daniele, Jason A Davis, et al.
European Journal of Heart Failure
|
March 21, 2024
Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA-HF and DELIVER data
Jason A Davis, David Booth, Phil McEwan, et al.
European Journal of Heart Failure
|
June 22, 2023
The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health-economic analysis of the DELIVER trial
David Booth, Jason A Davis, Phil McEwan, et al.
Clinical Kidney Journal
|
February 23, 2024
Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial
Phil McEwan, Jason A Davis, Peter D Gabb, et al.
Page
of 4